Company Overview

CEL-SCI Corporation is a U.S.-based biotechnology company focused on the development of immunotherapy products for the treatment of cancer, infectious diseases, and inflammatory conditions. The company operates within the biotechnology and biopharmaceutical industries, with its primary emphasis on immuno-oncology. CEL-SCI’s lead product candidate is Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy designed for the treatment of newly diagnosed locally advanced primary head and neck cancer prior to surgery and radiation. The company has also developed investigational technologies related to peptide-based immunotherapy and immune system modulation.

The company’s principal revenue driver has historically been capital raising activities rather than commercial product sales, as it remains in the clinical-stage biotechnology phase without approved commercial therapies. CEL-SCI positions itself around the concept of administering immune-based therapies early in the disease treatment cycle, particularly before conventional treatments may suppress immune function. Founded in 1983 and headquartered in Vienna, Virginia, the company has evolved from a broad immunotherapy research organization into a more focused oncology development company centered on advancing Multikine through clinical development and regulatory engagement.

Business Operations

CEL-SCI primarily operates through its biotechnology research and development activities, with operations centered on clinical trials, regulatory affairs, manufacturing, and intellectual property development. Its principal operating focus is the Multikine program, which has undergone a large international Phase III clinical trial targeting squamous cell carcinoma of the head and neck. The company also developed the LEAPS (Ligand Epitope Antigen Presentation System) technology platform, designed to direct immune responses for potential use in autoimmune and infectious diseases, though this platform remains at an earlier development stage compared with Multikine.

The company maintains manufacturing capabilities through its dedicated biologics manufacturing facility in Maryland, which supports investigational product production and process control activities. CEL-SCI’s operations include both domestic and international clinical engagement, with prior clinical trial activity conducted across multiple countries in North America, Europe, and Asia. The company has historically relied on collaborations with contract research organizations, clinical investigators, and specialized manufacturing and regulatory partners rather than maintaining large commercial subsidiaries or diversified operating divisions.

Strategic Position & Investments

CEL-SCI’s strategic direction centers on advancing Multikine toward potential regulatory approval and commercialization opportunities in oncology. The company has invested substantially in late-stage clinical trials, manufacturing infrastructure, and regulatory submissions associated with its immunotherapy platform. Management has emphasized the potential differentiation of Multikine based on its intended use before surgery and radiation treatment, positioning the therapy as a neoadjuvant immunotherapy approach within head and neck cancer care.

The company has also continued investment in its proprietary LEAPS technology platform for potential applications in rheumatoid arthritis and infectious diseases. While CEL-SCI does not maintain a broad portfolio of commercial subsidiaries or extensive acquisition activity comparable to larger pharmaceutical firms, it has focused on protecting intellectual property and sustaining long-term clinical development capabilities. Public disclosures indicate ongoing efforts to secure strategic partnerships, licensing opportunities, and potential commercialization arrangements tied to future regulatory outcomes.

Geographic Footprint

CEL-SCI is headquartered in Vienna, Virginia, with manufacturing operations located in Maryland. Although the company’s operational base is concentrated in the United States, its clinical development activities have historically involved multiple international regions, including parts of Europe, Asia, and North America through multinational clinical trial participation.

The company’s global footprint is primarily tied to research collaborations, regulatory engagement, and clinical trial execution rather than commercial sales infrastructure. Its international operational influence has been most visible through the large multinational Phase III study for Multikine, which involved clinical sites across numerous countries and healthcare systems. CEL-SCI does not currently maintain a broad global commercial distribution network due to its clinical-stage status.

Leadership & Governance

CEL-SCI was founded by Geert Kersten, who has served as a central figure in shaping the company’s long-term immunotherapy strategy. Leadership has consistently emphasized immune-system-based treatments designed to intervene earlier in disease progression, particularly in oncology settings. The company’s governance structure reflects a development-stage biotechnology model focused heavily on clinical advancement, regulatory oversight, manufacturing readiness, and capital management.

Key executives and leadership figures include:

• Geert Kersten – Chief Executive Officer
• Jeffrey W. Church – Chief Financial Officer
• Robert B. Watson – Chairman of the Board
• Mansoor Raza Mirza, M.D. – Chief Medical Officer
• Lawrence W. Stambaugh – Senior Vice President, Regulatory Affairs

The company’s leadership strategy has consistently focused on advancing proprietary immunotherapy technologies through clinical validation while maintaining internal manufacturing capabilities and protecting intellectual property assets through regulatory and patent frameworks.